HK1231397A1 - 包封修饰的环糊精复合物的脂质体组合物及其应用 - Google Patents

包封修饰的环糊精复合物的脂质体组合物及其应用 Download PDF

Info

Publication number
HK1231397A1
HK1231397A1 HK17105160.4A HK17105160A HK1231397A1 HK 1231397 A1 HK1231397 A1 HK 1231397A1 HK 17105160 A HK17105160 A HK 17105160A HK 1231397 A1 HK1231397 A1 HK 1231397A1
Authority
HK
Hong Kong
Prior art keywords
liposome compositions
modified cyclodextrin
cyclodextrin complexes
compositions encapsulating
encapsulating modified
Prior art date
Application number
HK17105160.4A
Other languages
English (en)
Chinese (zh)
Inventor
Vogelstein Bert
Zhou Shibin
W. Kinzler Kenneth
Sur Surojit
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Publication of HK1231397A1 publication Critical patent/HK1231397A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK17105160.4A 2014-01-14 2015-01-14 包封修饰的环糊精复合物的脂质体组合物及其应用 HK1231397A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461927233P 2014-01-14 2014-01-14
US61/927,233 2014-01-14
PCT/US2015/011342 WO2015108932A1 (en) 2014-01-14 2015-01-14 Liposome compositions encapsulating modified cyclodextrin complexes and uses thereof

Publications (1)

Publication Number Publication Date
HK1231397A1 true HK1231397A1 (zh) 2017-12-22

Family

ID=53543384

Family Applications (1)

Application Number Title Priority Date Filing Date
HK17105160.4A HK1231397A1 (zh) 2014-01-14 2015-01-14 包封修饰的环糊精复合物的脂质体组合物及其应用

Country Status (8)

Country Link
US (2) US20180161274A1 (enExample)
EP (1) EP3094313A4 (enExample)
JP (1) JP2017502985A (enExample)
CN (1) CN106659683A (enExample)
AU (1) AU2015206628A1 (enExample)
CA (1) CA2936963A1 (enExample)
HK (1) HK1231397A1 (enExample)
WO (1) WO2015108932A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3370712B1 (en) 2015-11-06 2025-02-19 The Johns Hopkins University 3-bromopyruvate for treating liver fibrosis
SG10202107836SA (en) * 2017-01-18 2021-08-30 Temasek Life Sciences Laboratory Ltd Hyperstabilized liposomes increase targeting of mitotic cells
CN108478533B (zh) * 2018-04-23 2020-12-08 滨州医学院 β环糊精-LPC脂质体制备方法及其作为药物载体的应用
CN112384226B (zh) * 2018-07-06 2024-06-28 丸大食品株式会社 含有缩醛磷脂的组合物
CN108853111B (zh) * 2018-08-07 2020-06-05 浙江大学 一种组合物在制备治疗吉非替尼肝脏毒性药物中的应用
CN111449187B (zh) * 2020-05-09 2022-10-14 扬州大学 一种布氏乳杆菌S-层蛋白修饰的香芹酚/β-环糊精脂质体及其制备方法和抗菌用途
EP4026945A1 (en) * 2021-01-07 2022-07-13 Calik Denim Tekstil San. Ve Tic. A.S. Encapsulated indigo
CN114113426B (zh) * 2021-12-27 2024-04-26 西安血氧生物技术有限公司 一种血红蛋白氧载体中磷脂的检测方法
CN115386262B (zh) * 2022-09-26 2023-05-12 杭州海维特化工科技有限公司 一种应用于汽车内饰装饰塑料膜的缓释香精和负离子的凹印水墨及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04500229A (ja) * 1988-08-31 1992-01-16 オーストレイリアン・コマーシヤル・リサーチ・アンド・デイベロツプメント・リミテツド 薬剤分配用及びクロマトグラフィー用の組成物及び方法
ES2036504A6 (es) * 1990-03-02 1993-05-16 Australian Commercial Research Procedimiento para preparar complejos de ciclodextrina.
AU6818094A (en) * 1993-04-22 1994-11-08 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
HU213200B (en) * 1993-05-12 1997-03-28 Chinoin Gyogyszer Es Vegyeszet The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
DE19814815C2 (de) * 1998-04-02 2000-10-12 Gerhard Steffan Sterinverknüpfte, anionische Cyclodextrinderivate und deren Verwendung in Arzneimittelformulierungen
CN1813679A (zh) * 2005-11-30 2006-08-09 上海医药(集团)有限公司 一种紫杉烷脂质体冻干组合物及其制备方法
CN101653414B (zh) * 2008-08-19 2011-07-20 中国科学院上海药物研究所 多西他赛长循环固体脂质纳米粒及其制备方法
EP2415464B1 (en) * 2009-03-30 2017-05-10 Eisai R&D Management Co., Ltd. Method for producing liposome composition
CN102596178B (zh) * 2009-10-26 2014-12-03 石药集团中奇制药技术（石家庄）有限公司 具有磺丁基醚环糊精盐内水相的脂质体
CN102397248A (zh) * 2010-09-15 2012-04-04 万物(北京)医药科技发展有限公司 一种辛二酰苯胺异羟肟酸环糊精包合物脂质体
ES2770575T3 (es) * 2010-10-28 2020-07-02 Pacira Pharmaceuticals Inc Formulación de liberación sostenida de un fármaco antiinflamatorio no esteroideo
WO2012118376A1 (en) * 2011-03-01 2012-09-07 To-Bbb Holding B.V. Advanced active liposomal loading of poorly water-soluble substances
WO2014004651A1 (en) * 2012-06-26 2014-01-03 The Johns Hopkins University Multifunctional tunable biomaterials for tissue engineering
WO2014121235A2 (en) * 2013-02-01 2014-08-07 Zoneone Pharma, Inc. Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes

Also Published As

Publication number Publication date
AU2015206628A1 (en) 2016-08-25
US20180161274A1 (en) 2018-06-14
WO2015108932A1 (en) 2015-07-23
EP3094313A4 (en) 2017-07-12
EP3094313A1 (en) 2016-11-23
CN106659683A (zh) 2017-05-10
JP2017502985A (ja) 2017-01-26
US20190328665A1 (en) 2019-10-31
CA2936963A1 (en) 2015-07-23

Similar Documents

Publication Publication Date Title
HK1231397A1 (zh) 包封修饰的环糊精复合物的脂质体组合物及其应用
HK1254843B (zh) 包含细菌菌株的组合物
MX2022015755A (es) Profarmacos de hormona paratiroidea (pth).
HK1254843A1 (en) Compositions comprising bacterial strains
HK1256498A1 (zh) 聚肽表位 rna
FR3021319B1 (fr) Peptides, compositions les comprenant et utilisations notamment cosmetiques
EP3291832A4 (en) Nanoparticle compositions for sustained therapy
PH12017500555A1 (en) Modified phosphpors and compositions thereof
EP3281958A4 (en) Modifying agent, and modified conjugated diene-based polymer produced using same
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
EP3220914A4 (en) Nanomaterial compositions, synthesis, and assembly
MA40460A (fr) Ciblage lysosomial et utilisation correspondante
EP3218860A4 (en) Providing online cardholer authentication services on-behalf-of issuers
MX2017000141A (es) Nanoparticulas terapeuticas dirigidas y metodos para elaborar y utilizar las mismas.
EP3261725A4 (en) Enhanced perfume compositions
ZA201803476B (en) Anti-cd22 antibody-maytansine conjugates and methods of use thereof
WO2016020210A8 (en) Factor viii formulation
AU2016361427A8 (en) Platinum anticancer agents
HK1255835A1 (zh) 用於治疗乙型肝炎的治疗组合物及方法
IL260679A (en) Cyclodextrin-based polymers, methods and compositions, as well as their applications
EP3532301A4 (en) WHEEL ASSEMBLY, PROCESSES AND APPLICATIONS
SG10201902499VA (en) Therapeutic nanoparticles and related compositions, methods and systems
EP3445387A4 (en) COMBINATION, THERAPEUTIC USES AND PROPHYLACTIC USES
EP3235517A4 (en) Deodorant, deodorant composition, and deodorizing product
EP3197488A4 (en) Compositions comprising ch505 envelopes, and trimers